Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,171 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sham Control Group Clear all

Conditions: Multiple Drug Use
Interventions: IBMT, NF; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Stress Urinary Incontinence
Interventions: Transcutaneous electrical stimulation (Elitone); Device
Lead sponsor: Elidah, Inc.; Industry
Eligibility: 21 Years to 75 Years · Female only
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Monroe, Connecticut

Conditions: Psoriasis
Interventions: Ustekinumab 45 mg, Ustekinumab 90 mg, Placebo; Drug
Lead sponsor: Janssen Biotech, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 40
States / cities: Birmingham, Alabama • Bakersfield, California • Irvine, California + 37 more

Conditions: Geographic Atrophy
Interventions: SAR446597, Sham Comparator; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 60 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 31
States / cities: Peoria, Arizona • Scottsdale, Arizona • Beverly Hills, California + 25 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Transcranial Direct Current Stimulation (tDCS), Sham tDCS + anodal tDCS; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Dry Age-related Macular Degeneration
Interventions: Risuteganib, Sham; Drug · Other
Lead sponsor: Allegro Ophthalmics, LLC; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Gilbert, Arizona • Phoenix, Arizona • Beverly Hills, California + 4 more

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Hyperbaric oxygen, Hyperbaric chamber; Drug · Device
Lead sponsor: National Baromedical Services; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 4
States / cities: Rochester, Minnesota • Lebanon, New Hampshire • Columbia, South Carolina + 1 more

Conditions: TBI Depression
Interventions: Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS), Sham Comparator: Sham Treatment; Combination Product · Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Behavior, Child, Disruptive Behavior, Executive Dysfunction, Attention-deficit, Anxiety, Depression, Stress
Interventions: Treatment App, Sham app; Behavioral
Lead sponsor: New York University; Other
Eligibility: 6 Years to 12 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain Syndrome, Pain Management
Interventions: B Braun HNS 12 nerve stimulator, B Braun HNS 12 nerve stimulator sham control; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Opioid Use Disorder
Interventions: active tDCS, sham tDCS; Device
Lead sponsor: Butler Hospital; Other
Eligibility: 21 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Aging Well, Walking, Difficulty, Hyperemia
Interventions: Home-based leg heat therapy, Home-based sham therapy; Other
Lead sponsor: University of North Texas Health Science Center; Other
Eligibility: 55 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Multiple Sclerosis, Spasticity
Interventions: Dry needling, Sham dry needling; Device
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Chronic Pancreatitis
Interventions: Celiac Plexus Block, Sham; Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Neck Pain, Posterior
Interventions: HVLAT manipulation, Sham HVLAT manipulation; Procedure
Lead sponsor: Loma Linda University; Other
Eligibility: 20 Years to 45 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: G2-TR intraocular implant containing travoprost, Sham surgery + active-comparator eye drops; Combination Product · Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: OSA, SCI/D, Upper Airway Exercise
Interventions: UA and RMT, Sham exercise; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Parkinson's Disease
Interventions: Active tDCS, Sham tDCS; Device
Lead sponsor: Tel-Aviv Sourasky Medical Center; Government
Eligibility: 25 Years to 90 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bipolar Depression
Interventions: Medtronic Percept RC System, One Month Blinded Discontinuation Period; Device · Behavioral
Lead sponsor: Wayne Goodman MD; Other
Eligibility: 22 Years to 64 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 4
States / cities: Boston, Massachusetts • Houston, Texas • Seattle, Washington

Conditions: Major Depressive Disorder
Interventions: Repetitive Transcranial Magnetic Stimulation; Device
Lead sponsor: Neuronetics; Other
Eligibility: 18 Years to 70 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 13
States / cities: Poway, California • Stanford, California • Chicago, Illinois + 9 more

Conditions: Proximal Muscle Strength, Proximal Muscle Lengthening
Interventions: myofascial release, blood flow restriction; Other · Device
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years to 30 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Chronic Kidney Diseases
Interventions: Mindfulness-based stress reduction (MBSR), Health enhancement program (HEP), Transcutaneous Vagus Nerve Stimulation (tVNS), Sham-transcutaneous Vagus Nerve Stimulation (tVNS); Behavioral · Device
Lead sponsor: Emory University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Retinal Detachment With Multiple Breaks, Unspecified Eye, Proliferative Vitreoretinopathy
Interventions: Intravitreal aflibercept injection, Sham control; Drug · Other
Lead sponsor: M. Ali Khan, MD; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema
Interventions: Aflibercept, foselutoclax; Drug
Lead sponsor: Unity Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 19
States / cities: Bakersfield, California • Beverly Hills, California • Huntington Beach, California + 16 more

Search by objective public record fields.

Brain Mechanisms of Reducing Polysubstance Use

Stress Incontinence Trial With Elitone Device

A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Remotely Supervised tDCS for Slowing ALS Disease Progression

A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration

Hyperbaric Radiation Sensitization of Head and Neck Cancers

Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Depression & Other Neuropsychiatric Symptoms After Traumatic Brain Injury (TBI)

Randomized Controlled Trial of a Behavioral Training App

Peripheral Neurostimulation for Nerve Block Placement

tDCS to Decrease Opioid Relapse (UH3)

Heat Therapy, Functional Capacity, and Vascular Health in Older Adults

Dry Needling in Multiple Sclerosis

CPB Versus Sham Treatment for Pain Management in Small Duct Chronic Pancreatitis

The Effect of Manipulation of the Cervical Spine on Pain Biomarkers

Clinical Study Comparing Two Models of a Travoprost Intraocular Implant

Novel by Upper Airway Respiratory Muscle Training to Treat OSA in Chronic SCI

The Effects of Multi-focal tDCS on Motor-cognitive Dysfunctions in Parkinson's Disease

Deep Brain Stimulation of Treatment-Resistant Bipolar Depression

Study of a Repetitive Transcranial Magnetic Stimulation (rTMS) Device for the Treatment of Major Depressive Disorder

Investigating Proximal Muscle Strength Effects by Incorporating Proximal Muscle Lengthening

Mindfulness in Chronic Kidney Disease

Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair

Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)